NADAC acquisition cost data for CORLANOR 5 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
| 55513080060 | $8.64 | 2022-07-01 | Rx |
Generic: IVabradine HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $21.5M | 37,224 | 7,673 | $7.44 |
| 2020 | $26.5M | 41,918 | 8,390 | $7.83 |
| 2021 | $31.3M | 44,918 | 9,627 | $8.42 |
| 2022 | $38.4M | 49,849 | 10,929 | $9.16 |
| 2023 | $47.3M | 55,305 | 12,415 | $9.95 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $5.0M | 5,873 | 1,655 |
| California | $4.2M | 4,897 | 1,133 |
| Texas | $3.7M | 4,126 | 983 |
| New York | $3.2M | 3,430 | 781 |
| Ohio | $2.5M | 3,027 | 671 |
| Pennsylvania | $1.6M | 2,010 | 419 |
| North Carolina | $1.6M | 2,048 | 486 |
| Illinois | $1.5M | 1,800 | 402 |
| Indiana | $1.5M | 1,692 | 392 |
| Michigan | $1.4M | 1,631 | 402 |
| Missouri | $1.4M | 1,645 | 363 |
| South Carolina | $1.4M | 1,485 | 349 |
| Tennessee | $1.3M | 1,491 | 349 |
| Georgia | $1.3M | 1,489 | 330 |
| New Jersey | $1.2M | 1,388 | 319 |
| Louisiana | $1.1M | 1,533 | 294 |
| Virginia | $971.6K | 1,145 | 316 |
| Kentucky | $931.5K | 1,196 | 250 |
| Arizona | $885.9K | 978 | 240 |
| Massachusetts | $874.9K | 928 | 205 |
| Wisconsin | $771.1K | 930 | 220 |
| Alabama | $763.7K | 889 | 193 |
| Oklahoma | $689.6K | 846 | 221 |
| Arkansas | $664.7K | 856 | 178 |
| Maryland | $627.5K | 653 | 165 |
| Connecticut | $604.3K | 667 | 151 |
| Colorado | $576.0K | 565 | 135 |
| Kansas | $543.6K | 689 | 135 |
| Washington | $520.1K | 626 | 152 |
| Mississippi | $474.6K | 636 | 116 |
| Nevada | $401.8K | 433 | 89 |
| Minnesota | $343.0K | 388 | 103 |
| Nebraska | $331.7K | 492 | 79 |
| West Virginia | $272.6K | 271 | 80 |
| Iowa | $244.7K | 342 | 65 |
| Oregon | $239.6K | 297 | 69 |
| Utah | $197.3K | 230 | 50 |
| Idaho | $174.6K | 202 | 54 |
| Delaware | $144.4K | 129 | 33 |
| New Hampshire | $132.2K | 118 | 29 |
| Hawaii | $124.0K | 133 | 34 |
| Montana | $123.8K | 148 | 35 |
| South Dakota | $104.1K | 161 | 21 |
| New Mexico | $101.3K | 146 | 34 |
| District of Columbia | $97.6K | 92 | 27 |
| Puerto Rico | $92.3K | 124 | 25 |
| Vermont | $88.3K | 70 | 19 |
| Rhode Island | $85.1K | 118 | 21 |
| Maine | $75.1K | 73 | 23 |
| North Dakota | $56.8K | 79 | 16 |
| Alaska | $24.0K | 32 | N/A |
| Wyoming | $11.7K | 14 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.